Nandy, Partha <br/><br/>
Population pharmacokinetics of doripenem based on data from phase 1 studies with healthy volunteers and phase 2 and 3 studies with critically ill patients.  [electronic resource] 

 -  Antimicrobial agents and chemotherapy  Jun 2010 
 - 2354-9 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1098-6596 
<br/><br/><label>Standard No.: </label>10.1128/AAC.01649-09  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adolescent<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Anti-Bacterial Agents--administration & dosage<br/>Bacterial Infections--drug therapy<br/>Bayes Theorem<br/>Carbapenems--administration & dosage<br/>Creatinine--metabolism<br/>Critical Illness<br/>Cross Infection--drug therapy<br/>Doripenem<br/>Female<br/>Humans<br/>Kidney--metabolism<br/>Male<br/>Metabolic Clearance Rate<br/>Middle Aged<br/>Models, Biological<br/>Nonlinear Dynamics<br/>Pneumonia, Bacterial--drug therapy<br/>Pyelonephritis--drug therapy<br/>Renal Insufficiency--metabolism<br/>Urinary Tract Infections--drug therapy<br/>Young Adult